A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.
Guy LaureysBarbara WillekensLudo VanopdenboschOlivier DeryckDominik SelleslagMiguel D'HaeseleerAnn De BeckerBénédicte DuboisDaan DierickxGaetano PerrottaVirginie De WildeVincent van PeschNicole StraetmansDominique DiveYves BeguinBart Van WijmeerschKoen TheunissenTessa KerreAnn Van de VeldePublished in: Acta neurologica Belgica (2018)
Multiple sclerosis is considered to be an immune mediated inflammatory disorder of the central nervous system. It mainly affects young, socioeconomic active patients. Although our armamentarium for this disease has significantly evolved in recent years some patients remain refractory to conventional therapies. In these cases, autologous hematopoietic stem cell transplantation can be considered as a therapeutic option. Decreasing morbidity, mortality, and increasing patient awareness have led to rising inquiry by our patients about this treatment option. With the aim of a standardized protocol and data registration, a Belgian working party on stem cell therapy in multiple sclerosis was established. In this paper, we report the consensus protocol of this working party on autologous hematopoietic stem cell transplantation in multiple sclerosis.
Keyphrases
- multiple sclerosis
- cell therapy
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- randomized controlled trial
- acute myeloid leukemia
- bone marrow
- peritoneal dialysis
- type diabetes
- cardiovascular disease
- stem cells
- mesenchymal stem cells
- electronic health record
- big data
- deep learning
- clinical practice
- middle aged